* Q1 EPS $0.09 vs est $0.07
* Q1 rev up 19 pct at $18.0 mln
* Backs FY10 outlook
* Shares up 3 pct in after-mkt trade
May 6 SciClone Pharmaceuticals Inc (SCLN.O)
posted a quarterly profit that beat market estimates, driven by
strong sales of its hepatitis B treatment Zadaxin in China and
lower research and development expenses.
Shares of SciClone were up 3 percent in after-market trade.
First-quarter net income was $4.2 million, or 9 cents a
share, compared with $96,000, or breakeven per share in the
Revenue for the quarter rose 19 percent to $18.0 million.
Analysts were expecting earnings of 7 cents on revenue of
$19.1 million, according to Thomson Reuters I/B/E/S.
For fiscal 2010, the company reaffirmed its profit outlook
between 31 cents and 35 cents a share, and revenue outlook
between $82 million and $85 million.
Analysts expect earnings of 35 cents on revenue of $83.5
Chief Executive Friedhelm Blobel said the company is
expanding Zadaxin sales in China through further penetration
into class 3 and 2 hospitals in Tier 1 and 2 cities.
Foster City, California-based SciClone sells Zadaxin, a
drug approved in China and other overseas markets, to treat
hepatitis B infections and to boost the immune systems of other
patients, including those with liver cancer.
Shares of the company rose 3 percent to $4.00 in after
market trade. They closed at $3.90 Thursday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Don